Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan society for hematopoietic cell transplantation working party

I. Kataoka, M. Kami, S. Takahashi, Y. Kodera, S. Miyawaki, N. Hirabayashi, Shinichiro Okamoto, N. Matsumoto, Y. Miyazaki, Y. Morishita, O. Asai, A. Maruta, T. Yoshida, M. Imamura, N. Hamajima, K. Matsuo, M. Harada, Shin Mineishi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Acute graft-versus-host disease (GVHD) increases post-transplant mortality and morbidity, but exerts a potent graft-versus-leukemia (GVL) effect. To clarify the impact of GVHD on outcome after transplant in aggressive diseases, patients with acute myeloid or lymphoblastic leukemia (AML, n = 366 or ALL, n = 255) in nonremission states, or chronic myelogenous leukemia (CML, n = 180) in accelerated phase (AP) or blastic crisis (BC), who received allogeneic hematopoietic stem cell transplantation (HSCT) from a related donor between 1991 and 2000, were analyzed. Significant improvement in overall and disease-free survival (DFS) was detected with grade I acute GVHD in AML (P = 0.0002 for overall survival and 0.0009 for DFS, respectively) and in CML (P = 0.0256 and 0.0366, respectively), while the trend towards improved survival was observed in ALL. Relapse rate was lower in grade I acute GVHD than in grade II in all three diseases, suggesting that treatment for grade II GVHD may compromise the GVL effect associated with GVHD. Chronic GVHD was found to suppress relapse in CML and ALL, but not in AML, although no improvement in survival was observed in any disease category. Our results suggest that treatment for grade II acute GVHD may need to be attenuated in transplant for refractory leukemias.

Original languageEnglish
Pages (from-to)711-719
Number of pages9
JournalBone Marrow Transplantation
Volume34
Issue number8
DOIs
Publication statusPublished - 2004 Oct

Fingerprint

Hematopoietic Stem Cell Transplantation
Cell Transplantation
Graft vs Host Disease
Japan
Leukemia
Tissue Donors
Transplants
Disease-Free Survival
Survival
Recurrence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Morbidity
Mortality
Therapeutics

Keywords

  • Acute graft-versus-host disease
  • Allogeneic transplantation
  • Leukemia
  • Nonremission

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan society for hematopoietic cell transplantation working party. / Kataoka, I.; Kami, M.; Takahashi, S.; Kodera, Y.; Miyawaki, S.; Hirabayashi, N.; Okamoto, Shinichiro; Matsumoto, N.; Miyazaki, Y.; Morishita, Y.; Asai, O.; Maruta, A.; Yoshida, T.; Imamura, M.; Hamajima, N.; Matsuo, K.; Harada, M.; Mineishi, Shin.

In: Bone Marrow Transplantation, Vol. 34, No. 8, 10.2004, p. 711-719.

Research output: Contribution to journalArticle

Kataoka, I, Kami, M, Takahashi, S, Kodera, Y, Miyawaki, S, Hirabayashi, N, Okamoto, S, Matsumoto, N, Miyazaki, Y, Morishita, Y, Asai, O, Maruta, A, Yoshida, T, Imamura, M, Hamajima, N, Matsuo, K, Harada, M & Mineishi, S 2004, 'Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan society for hematopoietic cell transplantation working party', Bone Marrow Transplantation, vol. 34, no. 8, pp. 711-719. https://doi.org/10.1038/sj.bmt.1704659
Kataoka, I. ; Kami, M. ; Takahashi, S. ; Kodera, Y. ; Miyawaki, S. ; Hirabayashi, N. ; Okamoto, Shinichiro ; Matsumoto, N. ; Miyazaki, Y. ; Morishita, Y. ; Asai, O. ; Maruta, A. ; Yoshida, T. ; Imamura, M. ; Hamajima, N. ; Matsuo, K. ; Harada, M. ; Mineishi, Shin. / Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan society for hematopoietic cell transplantation working party. In: Bone Marrow Transplantation. 2004 ; Vol. 34, No. 8. pp. 711-719.
@article{83b02ac73ed84ad6b60d9d95f2efe27f,
title = "Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan society for hematopoietic cell transplantation working party",
abstract = "Acute graft-versus-host disease (GVHD) increases post-transplant mortality and morbidity, but exerts a potent graft-versus-leukemia (GVL) effect. To clarify the impact of GVHD on outcome after transplant in aggressive diseases, patients with acute myeloid or lymphoblastic leukemia (AML, n = 366 or ALL, n = 255) in nonremission states, or chronic myelogenous leukemia (CML, n = 180) in accelerated phase (AP) or blastic crisis (BC), who received allogeneic hematopoietic stem cell transplantation (HSCT) from a related donor between 1991 and 2000, were analyzed. Significant improvement in overall and disease-free survival (DFS) was detected with grade I acute GVHD in AML (P = 0.0002 for overall survival and 0.0009 for DFS, respectively) and in CML (P = 0.0256 and 0.0366, respectively), while the trend towards improved survival was observed in ALL. Relapse rate was lower in grade I acute GVHD than in grade II in all three diseases, suggesting that treatment for grade II GVHD may compromise the GVL effect associated with GVHD. Chronic GVHD was found to suppress relapse in CML and ALL, but not in AML, although no improvement in survival was observed in any disease category. Our results suggest that treatment for grade II acute GVHD may need to be attenuated in transplant for refractory leukemias.",
keywords = "Acute graft-versus-host disease, Allogeneic transplantation, Leukemia, Nonremission",
author = "I. Kataoka and M. Kami and S. Takahashi and Y. Kodera and S. Miyawaki and N. Hirabayashi and Shinichiro Okamoto and N. Matsumoto and Y. Miyazaki and Y. Morishita and O. Asai and A. Maruta and T. Yoshida and M. Imamura and N. Hamajima and K. Matsuo and M. Harada and Shin Mineishi",
year = "2004",
month = "10",
doi = "10.1038/sj.bmt.1704659",
language = "English",
volume = "34",
pages = "711--719",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan society for hematopoietic cell transplantation working party

AU - Kataoka, I.

AU - Kami, M.

AU - Takahashi, S.

AU - Kodera, Y.

AU - Miyawaki, S.

AU - Hirabayashi, N.

AU - Okamoto, Shinichiro

AU - Matsumoto, N.

AU - Miyazaki, Y.

AU - Morishita, Y.

AU - Asai, O.

AU - Maruta, A.

AU - Yoshida, T.

AU - Imamura, M.

AU - Hamajima, N.

AU - Matsuo, K.

AU - Harada, M.

AU - Mineishi, Shin

PY - 2004/10

Y1 - 2004/10

N2 - Acute graft-versus-host disease (GVHD) increases post-transplant mortality and morbidity, but exerts a potent graft-versus-leukemia (GVL) effect. To clarify the impact of GVHD on outcome after transplant in aggressive diseases, patients with acute myeloid or lymphoblastic leukemia (AML, n = 366 or ALL, n = 255) in nonremission states, or chronic myelogenous leukemia (CML, n = 180) in accelerated phase (AP) or blastic crisis (BC), who received allogeneic hematopoietic stem cell transplantation (HSCT) from a related donor between 1991 and 2000, were analyzed. Significant improvement in overall and disease-free survival (DFS) was detected with grade I acute GVHD in AML (P = 0.0002 for overall survival and 0.0009 for DFS, respectively) and in CML (P = 0.0256 and 0.0366, respectively), while the trend towards improved survival was observed in ALL. Relapse rate was lower in grade I acute GVHD than in grade II in all three diseases, suggesting that treatment for grade II GVHD may compromise the GVL effect associated with GVHD. Chronic GVHD was found to suppress relapse in CML and ALL, but not in AML, although no improvement in survival was observed in any disease category. Our results suggest that treatment for grade II acute GVHD may need to be attenuated in transplant for refractory leukemias.

AB - Acute graft-versus-host disease (GVHD) increases post-transplant mortality and morbidity, but exerts a potent graft-versus-leukemia (GVL) effect. To clarify the impact of GVHD on outcome after transplant in aggressive diseases, patients with acute myeloid or lymphoblastic leukemia (AML, n = 366 or ALL, n = 255) in nonremission states, or chronic myelogenous leukemia (CML, n = 180) in accelerated phase (AP) or blastic crisis (BC), who received allogeneic hematopoietic stem cell transplantation (HSCT) from a related donor between 1991 and 2000, were analyzed. Significant improvement in overall and disease-free survival (DFS) was detected with grade I acute GVHD in AML (P = 0.0002 for overall survival and 0.0009 for DFS, respectively) and in CML (P = 0.0256 and 0.0366, respectively), while the trend towards improved survival was observed in ALL. Relapse rate was lower in grade I acute GVHD than in grade II in all three diseases, suggesting that treatment for grade II GVHD may compromise the GVL effect associated with GVHD. Chronic GVHD was found to suppress relapse in CML and ALL, but not in AML, although no improvement in survival was observed in any disease category. Our results suggest that treatment for grade II acute GVHD may need to be attenuated in transplant for refractory leukemias.

KW - Acute graft-versus-host disease

KW - Allogeneic transplantation

KW - Leukemia

KW - Nonremission

UR - http://www.scopus.com/inward/record.url?scp=6444227274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6444227274&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704659

DO - 10.1038/sj.bmt.1704659

M3 - Article

C2 - 15361916

AN - SCOPUS:6444227274

VL - 34

SP - 711

EP - 719

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -